News | May 24, 2011

Elixir Medical Receives CE Mark for DESyne Novolimus Eluting Coronary Stent System

May 24, 2011 — Elixir Medical Corporation, a developer of product platforms combining state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE Mark for its DESyne Drug Eluting Coronary Stent System for the treatment of coronary artery disease.

“The CE Mark approval represents a major accomplishment for the company and validates the impressive clinical results demonstrated with this system,” said Alexandre Abizaid, M.D., Ph.D., from the Instituto Dante Pazzanese de Cardiologia in Sao Paulo, Brazil, co-principal investigator for the EXCELLA II clinical trial. “With its thin polymer coating and low drug dose, Elixir’s DESyne platform will provide clinicians with technology that raises the bar for the treatment of patients with coronary artery disease.”

The DESyne stent elutes a novel macrocyclic lactone compound Novolimus. Nine-month clinical, angiographic and IVUS results from the EXCELLA II randomized clinical trial evaluating the Elixir DESyne Novolimus Eluting Coronary Stent System compared to the control Endeavor Zotarolimus Eluting Coronary Stent System demonstrated DESyne superiority (p

“The excellent flexibility of the DESyne platform, along with its proven efficacy and safety, make it a versatile workhorse system,” said Stefan Verheye, M.D., Ph.D. from ZNA Middelheim, Antwerpen, Belgium, the lead enroller in the EXCELLA II clinical trial. "This advanced-generation platform will be competitive with the best-in-class systems currently available."

Elixir intends to launch the DESyne product platform in the third quarter with a broad size matrix of diameters ranging from 2.5 mm to 3.5 mm and lengths ranging from 8 mm to 28 mm.

For more information: http://www.elixirmedical.com

Related Content

Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting | November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting | November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting | November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting | October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting | September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
Overlay Init